PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function. It is also developing p53 R273H mutation and other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
IPO Year: 2020
Exchange: NASDAQ
Website: pmvpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/13/2024 | $6.00 | Buy | Craig Hallum |
| 4/12/2024 | $5.00 | Buy | Jefferies |
| 12/27/2023 | $7.00 | Buy | Ladenburg Thalmann |
| 3/2/2022 | $30.00 | Perform → Outperform | Oppenheimer |
| 3/2/2022 | Perform → Outperform | Oppenheimer | |
| 9/22/2021 | $35.00 → $43.00 | Neutral → Buy | Goldman Sachs |
| 8/19/2021 | Perform | Oppenheimer | |
| 8/2/2021 | $56.00 | Buy | Guggenheim |
| 7/29/2021 | $63.00 | Buy | H.C. Wainwright |
SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
Craig Hallum initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $6.00
Jefferies initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $5.00
Ladenburg Thalmann initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $7.00
Oppenheimer upgraded PMV Pharmaceuticals from Perform to Outperform and set a new price target of $30.00
Oppenheimer upgraded PMV Pharmaceuticals from Perform to Outperform
Goldman Sachs upgraded PMV Pharmaceuticals from Neutral to Buy and set a new price target of $43.00 from $35.00 previously
Oppenheimer initiated coverage of PMV Pharmaceuticals with a rating of Perform
Guggenheim initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $56.00
H.C. Wainwright initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $63.00
Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the U.S., Europe, and Asia-Pacific; interim analysis expected by mid-2025 Dose-limiting toxicities observed in rezatapopt and Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) combination arm of Phase 1b PYNNACLE trial; rezatapopt 500 mg once-daily in combination with pembrolizumab 200 mg every three weeks established as maximum tolerated dose; due to limited clinical benefit at this dose, PMV is discontinuing enrollment in the Phase 1b combination arm PMV Pharmace
Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 60% of sites activated across the U.S., Europe, and Asia-Pacific; interim analysis from Phase 2 monotherapy expected by mid-2025 Eligibility criteria in ongoing Phase 1b rezatapopt and pembrolizumab combination arm of PYNNACLE trial adjusted to align with Phase 2 TP53 Y220C and KRAS wild-type patient population Cash, cash equivalents, and marketable securities of $212.9 million as of June 30, 2024, providing expected cash runway to end of 2026 PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuti
PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences in June. Management will also participate in one-on-one investor meetings. Jefferies Global Healthcare Conference (June 5 – 6, 2024) Format: Fireside ChatDate: Thursday, June 6, 2024 Time: 2:00 – 2:25 PM ET Goldman Sachs 45th Annual Global Healthcare Conference (June 10 – 13, 2024)
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, "PMV Pharma"))) today announced a partnership to develop Foundation Medicine's tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma's rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation. Across all human cancers, TP53 is the most frequently altered gene, with mutations occurring in approximately 50% of cancer cases.1 Historically, TP53 mutations have been considered undruggable despite its prevalence across c
Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT)First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients with TP53 Y220C and KRAS WT advanced solid tumors PRINCETON, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that the first patient has been dosed in the registrational, tumor-agnostic PYNNACLE Phase 2 trial of rezatapopt (PC14586) in pa
Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type, remains on track to initiate in Q1 2024Phase 1 analysis from the PYNNACLE Phase 1/2 study of rezatapopt in a subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutation selected as a late-breaking oral presentation at 2024 SGO Annual Meeting on Women's CancerUpdated Phase 1 PYNNACLE data presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across multiple tu
PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David Mack, Ph.D., President and Chief Executive Officer of PMV Pharmaceuticals, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference taking place in Boston, Massachusetts March 4-6, 2024. The company will also be available to meet one-on-one with institutional investors at the conference. Details about the fireside chat can be found below. TD Cowen 44th Annual Health Care ConferenceDate:Monday, March 4, 2024Time:2
Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30%Unaudited cash, cash equivalents, and marketable securities totaling approximately $229 million as of December 31, 2023, combined with cost savings from workforce reduction, is expected to extend cash runway to end of 2026PC14586 registrational Phase 2 clinical trial remains on track to initiate in 1Q24 PRINCETON, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today announced a strategic reduction of
PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical Development and Medical Affairs)Michael Carulli promoted to Chief Financial OfficerRobert Ticktin, General Counsel, will expand responsibilities to include management of OperationsTim Smith, Senior Vice President, Head of Corporate Development, will expand responsibilities to include Investor RelationsPC14586 registrational Phase 2 clinical trial remains on track to initiate in Q1 2024 PRINCETON, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and dev
Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across multiple tumor types with median duration of response of seven monthsAn overall response rate of 38% observed at the recommended Phase 2 dose of 2000 mg daily for the intended Phase 2 population of TP53 Y220C and KRAS wild-type patientsRegistrational Phase 2 clinical trial expected to initiate in Q1 2024Ongoing enrollment in the combination arm of the PYNNACLE study with PC14586 and KEYTRUDA® (pembrolizumab) PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP),
SC TO-I/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
10-Q - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
SC TO-I - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
10-Q - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
ARS - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
DEFA14A - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
DEF 14A - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, ", PMV Pharma", ))))) today announced a partnership to develop Foundation Medicine's tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma's rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation. Across all human cancers, TP53 is the most frequently altered gene, with mutations occurring in approximately 50% of cancer cases.1 Historically, TP53 mutations have been considered undruggable despite its prevalence across cancers.2 TP53 Y220C mutation is one of the most frequentl
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
Craig-Hallum analyst Albert Lowe initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating and announces Price Target of $6.
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.37) by 18.92 percent. This is a 28.57 percent increase over losses of $(0.42) per share from the same period last year.
Jefferies analyst Kambiz Yazdi initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating and announces Price Target of $5.
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation featured in a late-breaking oral presentation at 2024 SGO Annual Meeting Of the 15 patients in the efficacy evaluable population, seven patients achieved a confirmed partial response with a seven-month median duration of response and a favorable safety profileRezatapopt is a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type which is being evaluated in a registrational Phase 2 study
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced the appointment of Carol Gallagher, Pharm.D., to its Board of Directors. Dr. Gallagher brings more than 30 years of biotech leadership and expertise in drug development and commercialization. She replaces Thilo Schroeder, Ph.D., who is stepping down from the Board. The Board changes are effective immediately. "We are thrilled to welcome Carol to our Board. She is a recognized industry leader with a stellar track record of creating value. Her capabilities in
Continued progress with Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutationStrong cash, cash equivalents and marketable securities of $314.1 million as of December 31, 2021 CRANBURY, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided corporate highlights. "We expect that 2022 will be another pr
CRANBURY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the appointment of Kirsten Flowers to its Board of Directors. Concurrent with the appointment of Ms. Flowers, Peter Thompson, M.D. will resign from PMV's Board. "Peter has been an invaluable member of the Board during a period of substantial growth and key successes, including completion of our IPO as well as entry of our lead candidate, PC14586, into the clinic," said David Mack, Ph.D., President and Chief Executive Officer of PMV. "On behalf o
CRANBURY, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced the appointment of Tim Smith as Senior Vice President, Head of Corporate Development. "Tim's extensive experience and proven leadership in business and corporate development in both small and large biotechnology companies will be a key asset for PMV Pharma as we continue to maximize the full potential of our pipeline of tumor-agnostic p53 targeted therapies," said David Mack, Ph.D., President and Chief Executive Officer of PMV. "We are delighted to
CRANBURY, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced the appointment of Charles M. Baum, M.D., Ph.D., to its Board of Directors. "Chuck is a recognized biopharma leader who has made significant contributions in the advancement of precision oncology,” said David Mack, Ph.D., President and Chief Executive Officer of PMV. “His strong track record of success in building innovative oncology portfolios, from development through commercial launch, will be an ideal complement to our Board as we navigate ou
CRANBURY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced the appointment of Guillermina (Gigi) Lozano, Ph.D., to its Scientific Advisory Board (SAB). "Gigi’s work in p53 biology has had a tremendous impact on our fundamental understanding of the p53 pathway and the consequences of p53 mutations in cancer,” said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma. “We welcome Gigi and look forward to her participation on our SAB.” Dr. Guillermina (Gigi) Lozano is a geneticist recognize